Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694713 | 0.86 | SIGMAR1 (0.70) | KMT2ASIGMAR1 | |
| SCHEMBL6700050 | 0.83 | MEN1 (0.45) | MEN1MAPTKMT2AEPHX1P2RX7 | |
| SCHEMBL6701300 | 0.82 | KDM4E (0.52) | MEN1MAPTKMT2AEPHX1P2RX7 | |
| SCHEMBL6702001 | 0.81 | MTNR1A (0.59) | MEN1MAPTKMT2AP2RX7CHRNB2 | |
| SCHEMBL6704247 | 0.80 | ALDH1A1 (0.61) | MEN1KMT2AEPHX1HPGD | |
| SCHEMBL6698788 | 0.79 | MEN1 (0.45) | MEN1MAPTKMT2AP2RX7CHRNB2 | |
| SCHEMBL6698864 | 0.79 | MEN1 (0.43) | MEN1MAPTKMT2AP2RX7CHRNB2 | |
| SCHEMBL6702035 | 0.78 | KMT2A (0.55) | MEN1MAPTKMT2AP2RX7CHRNB2 | |
| SCHEMBL6698878 | 0.78 | MEN1 (0.44) | MEN1MAPTKMT2AEPHX1P2RX7 | |
| SCHEMBL2751955 | 0.78 | SIGMAR1 (0.70) | MEN1KMT2AEPHX1SIGMAR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044037-A1 | Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis | HONG YUFENG (US) | 2004-03-04 | — | — | US | disclosed |
| EP-1332127-A2 | AMIDINO-UREA SEROTONIN RECEPTOR LIGANDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND METHODS FOR THEIR SNYTHESIS | Warner-Lambert Company LLC (US) | 2003-08-06 | — | — | EP | disclosed |
| WO-2002036554-A2 | AMIDINO-UREA SEROTONIN RECEPTOR LIGANDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND METHODS FOR THEIR SNYTHESIS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044037-A1 | Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis | HTR7, HTR1A, HTR2C | MEN1 3611/4885MAPT 2819/4885KMT2A 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.